Pricing

Xarelto Lawsuit Cases Granted MDL Status By JPML

Download as PDF Single Release RSS Feed
Facebook Twitter Reddit LinkedIn Email

TheProductLawyers.com offers insight on the latest developments in the more than 2,800 cases against Xarelto and its manufacturers, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson.) In October of 2015, plaintiffs collectively approached the U.S. Judicial Panel on Multidistrict litigation (JPML) with a request for consolidation of cases with similar allegations. They further requested that the trials be held in the Southern District of Illinois. The defendants protested this, citing New Jersey as a more logical venue since many of their corporate offices are based in that state.

Following many weeks of formal hearings and deliberation, the JPML issued their statement on December 4th, 2015. Given the body of evidence evaluated, they stated, "In our judgment, the considerable growth in the litigation over the past few months demonstrates that informal coordination is not practical." They then agreed to create a multidistrict litigation for the plaintiffs, citing conservation of public and private resources as the foundation for the motion. Additionally, they dictated that the proceedings would be held in the neutral location of the Eastern District of Louisiana to forestall further contention.

The consolidation, which became official on December 12th, also serves the interests of all parties by precluding the potentially variable verdicts of multiple judges. To this end, they made their choice of judge clear, observing that, "Judge Eldon E. Fallon, who presides over three potential tag-along actions, is an experienced transferee judge with the willingness and ability to manage this litigation efficiently."

They are confident in his prudent sense of the law and his competent management of cases. Plaintiffs are confident that additional cases will continue to swell their numbers as the cases proceed to court. In Pennsylvania, a mass tort program comprising 550 individual cases is was consolidated by the Philadelphia Court of Common Pleas. Plaintiffs in the MDL view this development as a confirmation of the pressing need for resolution of stated grievances against Xarelto's manufacturers.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

Download as PDF Single Release RSS Feed
Facebook Twitter Reddit LinkedIn Email

About TheProductLawyers.com :

TheProductLawyers.com is a resource website sponsored by Banville Law to provide information on pending lawsuits against defective products, drugs and medical devices.

Contact TheProductLawyers.com:

Banville Law

165 West End Ave #1h,
New York, NY 10023

888-478-9711

Additional News Releases From TheProductLawyers.com:

November 30, 2016Research Indicates New Form Of Treating Ovarian Cancer As Talcum Powder Lawsuit Numbers Climb

November 30, 2016Parties in Talcum Powder Lawsuit In Missouri Exchange Briefings

November 30, 2016J&J Requests Disclosure Of Third Party Litigation Financing In Talcum Powder Lawsuit

November 30, 2016Delaware Sees 10 New Talcum Powder Lawsuit Filings

November 29, 2016Philadelphia Talcum Powder Lawsuit Filed Against Johnson & Johnson To Proceed

November 29, 2016Pennsboro Woman Files Talcum Powder Lawsuit On Behalf Of Her Deceased Mother

November 29, 2016Bioimaging Helps Early Detection Of Ovarian Cancer As Talcum Powder Lawsuit Filings Continue

November 28, 2016FDA Follow-Up: How Officials Have Responded To The Influx Of Talcum Powder Lawsuit Filings

November 28, 2016Talc Uses: A Look At The Product At The Center Of Talcum Powder Lawsuit Filings

November 28, 2016More Women Encouraged To File A Talcum Powder Lawsuit After Verdicts